Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2022

28-04-2022 | Breast Cancer | Epidemiology

Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study

Authors: Zahna Bigham, Yvonne Robles, Karen M. Freund, Julie R. Palmer, Kimberly A. Bertrand

Published in: Breast Cancer Research and Treatment | Issue 1/2022

Login to get access

Abstract

Purpose

Compared to white women, Black women have increased risk of developing hypertensive diseases of pregnancy (HDOP) and have a higher incidence of aggressive breast cancer subtypes. Few studies of HDOP and breast cancer risk have included large numbers of Black women. This study examined the relation of HDOP to incidence of breast cancer overall and by estrogen receptor (ER) status in Black women.

Methods

We followed 42,982 parous women in the Black Women’s Health Study, a nationwide prospective study of Black women. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) to assess associations of self-reported HDOP, including preeclampsia and gestational hypertension, with breast cancer incidence overall and by ER subtype, adjusted for age and established breast cancer risk factors.

Results

Over 20 years of follow-up, we identified 2376 incident breast cancer cases. History of HDOP (11.7%) was not associated with breast cancer risk overall (HR 0.98; 95% CI 0.87, 1.11). HRs for invasive ER+ and ER– breast cancer were 1.11 (95% CI 0.93, 1.34) and 0.81 (95% CI 0.61, 1.07), respectively.

Conclusions

HDOP was not associated with risk of overall breast cancer in Black women. A suggestive inverse association with ER– breast cancer may reflect an anti-tumorigenic hormone profile in HDOP, but those results require confirmation in other studies.
Literature
5.
go back to reference Fingar K, Mabry-Hernandez I, Ngo-Metzger Q, et al (2017) Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005–2014. HCUP Statistical Brief. Agency for Healthcare Research and Quality, Rockville, MD Fingar K, Mabry-Hernandez I, Ngo-Metzger Q, et al (2017) Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005–2014. HCUP Statistical Brief. Agency for Healthcare Research and Quality, Rockville, MD
17.
go back to reference Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRef Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRef
34.
go back to reference Rosenberg L, Adams-Campbell L (1972) The Black Women’s health study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50:56–58 Rosenberg L, Adams-Campbell L (1972) The Black Women’s health study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc 50:56–58
46.
go back to reference Hübinette A, Lichtenstein P, Brismar K et al (2003) Serum insulin-like growth factors in normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 82:1004–1009PubMed Hübinette A, Lichtenstein P, Brismar K et al (2003) Serum insulin-like growth factors in normal pregnancy and in pregnancies complicated by preeclampsia. Acta Obstet Gynecol Scand 82:1004–1009PubMed
56.
go back to reference Troisi R, Weiss HA, Hoover RN et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRef Troisi R, Weiss HA, Hoover RN et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRef
Metadata
Title
Hypertensive diseases of pregnancy and risk of breast cancer in the Black Women’s Health Study
Authors
Zahna Bigham
Yvonne Robles
Karen M. Freund
Julie R. Palmer
Kimberly A. Bertrand
Publication date
28-04-2022
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2022
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06606-3

Other articles of this Issue 1/2022

Breast Cancer Research and Treatment 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine